| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
LY83583 targets soluble guanylate cyclase (sGC). It acts as a competitive inhibitor of this enzyme, which is responsible for converting GTP to cGMP. The compound also blocks the release of intracellular Ca2+ and antigen-induced leukotrienes.
|
|---|---|
| ln Vitro |
LY83583 inhibits soluble guanylate cyclase with an IC50 of 2 μM. It has been shown to inhibit leukotriene synthesis in guinea pig lung and rat peritoneal cells in vitro. The compound also blocks the release of intracellular Ca2+ and antigen-induced leukotrienes.
|
| ln Vivo |
In vivo, LY83583 inhibits cGMP production and modulates cGMP-mediated signaling pathways. The compound has been used to study the role of the nitric oxide-cGMP pathway in various physiological and pathological processes. Its effects on tumor cell proliferation have been investigated.
|
| Enzyme Assay |
In vitro enzyme assays measure the activity of soluble guanylate cyclase by monitoring the conversion of GTP to cGMP. LY83583 is incubated with purified sGC or tissue homogenates, and cGMP production is measured by radioimmunoassay or ELISA. The IC50 is determined from the inhibition of enzyme activity.
|
| Cell Assay |
In vitro cellular assays evaluate the effects of LY83583 on cGMP levels in cultured cells. Cells are treated with the compound, and intracellular cGMP is measured by immunoassay. The compound's effects on cell proliferation and p21 expression are also assessed in cancer cell lines. Calcium mobilization and leukotriene release assays may also be performed.
|
| Animal Protocol |
In vivo animal experiments are conducted to study the role of the cGMP pathway in various physiological processes. LY83583 is administered via intraperitoneal or intravenous injection. cGMP levels in tissues are measured, and physiological responses such as vasodilation or platelet aggregation are assessed.
|
| ADME/Pharmacokinetics |
LY83583 has a molecular formula of C15H10N2O2 and is also known as 6-anilino-5,8-quinolinequinone. It has a molecular weight of approximately 250.26. The compound is soluble in DMSO. It should be stored at -20°C. The compound has a purity of ≥95%.
|
| Toxicity/Toxicokinetics |
The toxicity profile of LY83583 is consistent with its mechanism as a guanylate cyclase inhibitor. Inhibition of cGMP production can affect multiple physiological processes including vasodilation and platelet function. The compound is used primarily as a research tool and its toxicity has been evaluated in the context of preclinical studies.
|
| References | |
| Additional Infomation |
6-Aniline-5,8-quinolinedione is a quinolone compound with the structure quinolin-5,8-dione, where the hydrogen at the 6-position is replaced by an aniline group. It possesses antitumor activity and is also an EC 4.6.1.2 (guanylate cyclase) inhibitor. It belongs to the quinolone class, aminoquinoline class, aromatic amine class, and is a paraquinone compound.
LY83583 is a biochemical compound used primarily in research to study the regulation of cGMP levels in cells. It is also known as 6-anilinoquinoline-5,8-quinone. The compound has been used to investigate the role of the nitric oxide-cGMP pathway in various physiological and pathological processes. |
| Molecular Formula |
C15H10N2O2
|
|---|---|
| Molecular Weight |
250.25
|
| Exact Mass |
250.074
|
| Elemental Analysis |
C, 71.99; H, 4.03; N, 11.19; O, 12.79
|
| CAS # |
91300-60-6
|
| PubChem CID |
3976
|
| Appearance |
Brown to red solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
446.9±45.0 °C at 760 mmHg
|
| Melting Point |
184-185°C
|
| Flash Point |
224.1±28.7 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.715
|
| LogP |
1.56
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
410
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C2C(=CC=CN=2)C(=O)C(NC2C=CC=CC=2)=C1
|
| InChi Key |
GXIJYWUWLNHKNW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10N2O2/c18-13-9-12(17-10-5-2-1-3-6-10)15(19)11-7-4-8-16-14(11)13/h1-9,17H
|
| Chemical Name |
6-anilinoquinoline-5,8-dione
|
| Synonyms |
LY 83583; LY-83583; LY83583
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~200 mg/mL (~799.2 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9960 mL | 19.9800 mL | 39.9600 mL | |
| 5 mM | 0.7992 mL | 3.9960 mL | 7.9920 mL | |
| 10 mM | 0.3996 mL | 1.9980 mL | 3.9960 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
